Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The majority of Men C conjugate vaccines given in the UK use CRM(197), a mutant diphtheria toxoid, as their protein carrier. We studied the effects of prior immunisation with Men C-CRM(197) conjugate vaccine on immunity to diphtheria in 193 children before and after a booster dose of Men C at 4 years. Baseline diphtheria antibodies were higher in children given four previous doses of Men C (P<0.0001) and tended to be higher following boosting in those who had received three or four doses. This enhanced immunity was not associated with increased reactogenicity.

Type

Journal article

Journal

Vaccine

Publication Date

02/06/2003

Volume

21

Pages

2573 - 2579

Keywords

Child, Preschool, Diphtheria, Diphtheria Toxoid, Follow-Up Studies, Humans, Immunization Schedule, Infant, Meningococcal Infections, Meningococcal Vaccines, Reproducibility of Results, Time Factors, Vaccines, Conjugate